Propanc Biopharma, Inc. (PPCB)
Healthcare · NCM
Fundamentals
Valuation and ratings
Propanc Biopharma, Inc. trades at USD1.37, which is 120% below the USD3.01 our discounted cash flow model puts on the business. On that measure alone it screens as undervalued, though a DCF is an argument rather than a measurement, and the market is frequently right about why something is cheap.
Our moat model scores it 10 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 0.0 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
PPCB dividend history
No individual payments are on record for this listing, so the current facts above are all we can honestly show.
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.
PPCB passes 2 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Common questions
Is Propanc Biopharma, Inc. (PPCB) undervalued?
Against our discounted cash flow estimate of USD3.01, PPCB at USD1.37 is 120% below fair value. That is one model's answer, not a recommendation, and most of a DCF's output sits in a terminal value nobody can forecast.
What is PPCB's P/E ratio?
PPCB trades at 0.0 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
The full research page for PPCB, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.